Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

61.51 UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 61.51
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 61.51
Today's Range 61.51 - 61.51
52wk Range 39.49 - 73.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:  
Via Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck... 
Via Benzinga

Performance

YTD
-7.29%
-7.29%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+51.13%
+51.13%

More News

Read More
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Via The Motley Fool
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Via MarketBeat
Exposures Product Safety
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
Via Benzinga
Daily Stock Analysis: Eisai
Via Talk Markets
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
Via Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
Via Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Via Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Via Benzinga
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Via Benzinga
Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories
Via Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
Via Benzinga
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
Via Benzinga
After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer
Via Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Via Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Via Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Via Benzinga
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
Via Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
Via Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.